Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen

Baral, Rathindra Nath; Saha, Asim; Chatterjee, S. K.; Foon, Kenneth A.; Krieg, Arthur Μ.; Weiner, George J.; Bhattacharya‐Chatterjee, Malaya

doi:10.1007/s00262-002-0351-x

Cited by 27 publications

(3 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CEA has also been used in active vaccination strategies against diverse CEA‐expressing cancers because of its exclusive expression on oncofetal tissues and its role in tumorigenesis [2,7]. Over the past few years, CEA‐specific immune responses have been induced in vitro and in vivo that could suppress growth of CEA‐positive cancers in mouse studies [8–11] as well as in human trials [12,13]. Among the immunotherapies using CEA, dendritic cell (DC)‐based vaccinations showed promising results in mice but were not satisfactory in clinical trials [2].…”

Section: Introductionmentioning

confidence: 99%

Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli

Bae

Cho

Seong

2009

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli

Bae

Cho

Seong

2009

Clinical and Experimental Immunology

View full text Add to dashboard Cite

“…T Cell Proliferation Assay-Spleen cells from 2 randomly selected BALB/c mice, which were immunized 4 times with GST-H98 or GSTother peptide, were isolated according to the standard techniques on day 7 post-immunization (17). 96-Well microtiter plates were coated with peptide H98 at different concentrations (0, 1, 10, and 100 g/ml) and then washed twice with PBS.…”

Section: Methodsmentioning

confidence: 99%

A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2

Jiang

Liu

et al. 2005

Journal of Biological Chemistry

View full text Add to dashboard Cite

Trastuzumab, a humanized antibody to HER-2, has been shown to be effective in the treatment of breast cancer in which HER-2 overexpression and metastasis occurs. In our search for an effective mimic epitope of HER-2 binding with trastuzumab and to develop HER-2 peptide vaccine, we screened a phage display 12-mer peptide library with trastuzumab as the target. A mimetic peptide (mimotope) H98 (LLGPYELWELSH) that could specifically recognize trastuzumab was isolated. The DNA encoding peptide H98 was cloned and expressed as the fusion protein GST-H98 in Escherichia coli BL21. The purified GST-H98 could specifically bind to trastuzumab and block the binding of trastuzumab to HER-2 protein. Moreover, H98 could significantly block the function of trastuzumab inhibiting the growth of cancer cells. Mice that were immunized with GST-H98 made specific antibody to H98 as well as to HER-2. In addition, T-cell proliferation occurred in mice immunized with GST-H98. Although no sequence homology was found between H98 and HER-2, through the use of structure analysis we were able to determine that peptide H98 contributed to a conformational epitope of HER-2. Furthermore, we determined that the last two amino acids at the C terminus, and the third together with the fourth amino acid at the N terminus of peptide H98 are critical to the binding of H98 to trastuzumab. As a result, we conclude that peptide H98 has potential for being developed as a HER-2 vaccine for biotherapy of cancer with HER-2 overexpression.

show abstract

“…The authors have developed a murine anti-Id mAb designated 3H1 (CeaVac, NIH/Titan Pharmaceuticals), which mimics a specific epitope of CEA (Bhattacharya-Chatterjee et al, 1990). The authors' initial studies in C57BL/6 naive mice suggested that 3H1 could be used as a surrogate antigen for CEA and induced high-titer anti-CEA antibody as well as CD4 + T-helper (Th1) responses, which protected mice from tumor growth after challenge with lethal doses of syngeneic murine colon carcinoma cells, MC-38-expressing human CEA (Pervin et al, 1997;Baral et al, 2003;Saha et al, 2003). 3H1 also showed promise as a potential vaccine candidate in the phase I/II clinical trials of colon cancer patients (reviewed in Bhattacharya-Chatterjee et al, 2002).…”

Section: 86mentioning

confidence: 99%

Carcinoembryonic Antigen Transgenic Mouse Models for Immunotherapy and Development of Cancer Vaccines

Bhattacharya‐Chatterjee

Saha

Foon

et al. 2008

CP in Immunology

Self Cite

View full text Add to dashboard Cite

The goal of cancer therapy remains as the long-term eradication of tumor cells without adverse effects on normal tissue. Conventional approaches utilizing chemotherapy and radiotherapy are limited by both their toxicity and lack of specificity. In recent years, investigators have carried out several studies designed to evaluate whether human tumor-associated antigens (TAAs) can be exploited as targets for immunotherapy, specifically for human cancer vaccine development. A major limitation in immunotherapy studies of human cancer is the general lack of appropriate preclinical models. Clinical studies can be difficult to implement, particularly when a clear understanding of the potential efficacy, limitation, and safety of an immunotherapeutic strategy is not available from relevant animal investigations. However, mice carrying a transgene for a human tumor self-antigen may provide a more acceptable experimental model in which knowledge about immunotherapeutic strategies aiming at the TAA of interest can be enhanced prior to initiating clinical trials. Since the different strategies in experimental immunotherapy of cancer have been directed to activate different immune system components, a variety of transgenic mouse models have been generated expressing either TAA, human leukocyte antigen (HLA), oncogene, or immune effector cell molecules. These models may serve as an excellent platform for the identification of novel targets for immunotherapy as well as to evaluate the efficacy of targeted therapies and will lead to the development of clinical trials for cancer patients. In this unit, a brief overview of the generation and study of different vaccine approaches in carcinoembryonic antigen (CEA) transgenic mouse models and the experimental findings in mouse models that spontaneously develop gastrointestinal tumors and express the CEA transgene is provided.

show abstract

Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen

Cited by 27 publications

References 23 publications

Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli

Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli

A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2

Carcinoembryonic Antigen Transgenic Mouse Models for Immunotherapy and Development of Cancer Vaccines

Contact Info

Product

Resources

About